The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsCMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant RecipientsLetermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirusCytomegalovirus infection in transplant recipientsCMV: Prevention, Diagnosis and TherapyClinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationHuman CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigmDirect and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney TransplantationState-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinicianFlow cytometry and solid organ transplantation: a perfect matchThe Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ TransplantationInfection in Organ Transplantation.Antiviral drug resistance of human cytomegalovirus.Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran.Management of cytomegalovirus infection and disease in liver transplant recipients.A Systematic Review and Meta-analysis of Prophylactic versus Pre-emptive Strategies for Preventing Cytomegalovirus Infection in Renal Transplant Recipients.Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation.Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipientsIMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis.Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialRandomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxisEfficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation.Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.The biology of cytomegalovirus drug resistanceHomozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation.Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.Cytomegalovirus: recent progress in understanding pathogenesis and controlAccuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation.Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy.Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Transplant Infectious Diseases: A Review of the Scientific Registry of Transplant Recipients Published Data.Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor OrgansIsolated unilateral cytomegalovirus retinitis: a rare long-term complication after pediatric liver transplantation.Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patientsPlasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant RecipientsCytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy.Cytomegalovirus disease in African-American kidney transplant patients
P2860
Q24200697-B149E6A6-B0FA-4772-9D71-17551520E960Q24200991-3A850857-E4E4-404B-A924-05D70D108286Q26768473-62B535B4-8F4A-4ACA-9A0A-A082853324C2Q26783282-F769E994-DC67-4A64-8127-0D1BAD4789B4Q26801802-BD928CAF-1BE4-4F82-B21B-17D887A5A480Q26824869-418354DE-21BC-47D6-BB76-ADD15DB31097Q26826856-E8B346D5-BB19-4067-AEC8-C6ABD12737ACQ26850340-C176FE3A-BD09-4243-8952-30CC7A8F913EQ26863724-2A6237D4-FF78-46B6-AF42-08F0591726DFQ27014778-AFC2D4E1-3956-4003-A2BE-E22CFECECC9BQ27026499-0008AC96-5754-4354-9744-70907B2FDD10Q28085440-ED0AB8B2-55D8-4A84-85C4-10DAD28BACF6Q30238810-CD82801E-46F5-407B-9B5C-FB07075D90E0Q30430427-C9015E90-B36D-4260-AC5B-DC156580CEFCQ33624126-B78B6886-D6E6-4257-8789-777CDB162664Q33845124-C61830C0-02F1-4C66-8D75-AF97E4182F4BQ33871850-E2EC0821-CDBC-4828-BED5-04433A51BB53Q33911369-445D131B-F13E-4CA8-A481-6F6865A88FCAQ33912913-57DA3A2D-F527-4DA3-AAB6-72A2905DCD4CQ33932079-D4810341-FE54-4F96-9DE1-2EA00F3AA340Q34690629-06CC264D-9AAD-439C-956A-6F64913426C2Q34786700-2EA42B1B-08AA-44E0-BD36-21C89163EC4EQ35051236-B00F0FB4-13CB-4B03-8687-92854B70843DQ35140692-077A0970-05A5-4D7E-8E9B-D5A0D18C6147Q35196219-5658FE45-36E3-4EA5-A411-4B60EF0D2356Q35592509-9F7B3A1D-461A-45D4-B00F-E6D1A891AACAQ35684511-2219B0C3-6B5D-4D4A-9755-ADCFC55E6F25Q35694674-FC9EEABE-D63D-4EA7-A7C9-FBFF60B24513Q35785403-57CEC425-F4A2-4E56-8494-6E1F3671DA7DQ35895910-E28897C5-A251-4456-8941-A18B2FB9B422Q35990217-1CFB2D92-71BA-409D-B0CC-C2AB4D0DF4C8Q36147994-C701B644-E486-464E-9069-D969516B25B1Q36200933-9582DEB5-E9CF-4296-A9E7-8CD63606AAA4Q36244128-768ECAAC-AD51-40D1-B374-DB7498D22F5DQ36262672-0A509B3E-8BD1-4215-96AA-7CC1083E6BB6Q36288302-69175A76-1F1A-4955-B355-7C8948202BFBQ36321541-3C2FEC55-9FD1-4E43-BE15-B46829941445Q36389162-7358E974-4D70-42A9-83B3-26415B92B108Q36434411-88E80EE6-9D98-4D26-B713-99BC9DAD0FA8Q36614140-EB713F99-F260-4CEC-9860-11E16077A4A4
P2860
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The efficacy and safety of 200 ...... kidney transplant recipients.
@en
The efficacy and safety of 200 ...... kidney transplant recipients.
@nl
type
label
The efficacy and safety of 200 ...... kidney transplant recipients.
@en
The efficacy and safety of 200 ...... kidney transplant recipients.
@nl
prefLabel
The efficacy and safety of 200 ...... kidney transplant recipients.
@en
The efficacy and safety of 200 ...... kidney transplant recipients.
@nl
P2093
P1476
The efficacy and safety of 200 ...... kidney transplant recipients.
@en
P2093
A P Limaye
A T Voulgari
E A Blumberg
F Vincenti
I A Hauser
Y Lebranchu
P304
P356
10.1111/J.1600-6143.2010.03074.X
P407
P577
2010-03-26T00:00:00Z